Summary

Overview
The global epidural abscess treatment market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031 growing with a CAGR of XX% during the forecast period 2024-2031.
An epidural abscess is an infection within the epidural space anywhere in the brain or spinal cord. Epidural abscesses occur as a result of infections involving the spinal or cranial epidural space. Intracranial epidural abscesses (IEA) are complications of cranial surgery or trauma, they may also develop as complications of otorhinolaryngological infections or other neck and thoracic procedures.
The epidural abscess treatment market includes antibiotics such as vancomycin, gentamicin, and ceftriaxone are commonly used to treat epidural abscesses, often in combination with surgical intervention. Antifungal medications may be used in cases of fungal epidural abscesses and surgical procedures like decompression, open or minimally invasive techniques are often required to drain the abscess and relieve pressure on the spinal cord or brain. Surgery is the first line of treatment for epidural abscess infection.
Market Dynamics: Drivers
Rising prevalence of neurological disorder
The demand for the global epidural abscess treatment market is driven by multiple factors. One of the primary factors is the rising prevalence of neurological disorders. Neurological disorders encompass medical conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. The rising prevalence of neurological disorders, such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS), is another significant factor driving the epidural abscess treatment market.
According to Medspace Neurology in May 2022, the incidence of spinal epidural abscess presenting to large tertiary care centers is estimated to be about 0.2-2.8 cases per 10,000 admissions.
Similarly, in May 2023, the Centers for Disease Control and Prevention (CDC) continues to investigate increased reports of brain abscesses in children, which includes a 2022 cluster from Nevada's Clark County that was detailed last week at the CDC Epidemic Intelligence Service (EIS) annual meeting in Atlanta.
Epidural abscess treatment is a crucial approach for managing these neurological disorders. It typically involves timely surgical drainage of the abscess and antibiotic therapy, which helps prevent compression of the spinal cord and nerves, relieving pressure. For instance, in March 2022, the Alzheimer's Association, a nonprofit organization in the United States, reported that the number of Americans aged 65 and older living with Alzheimer's is expected to increase from an estimated 6.7 million in 2023 to 12.7 million by 2050. As neurological disorders become more prevalent, the demand for effective epidural abscess treatment market.
Restraints
Factors such as the high cost of treatment, limited awareness among individuals, complications & adverse effects associated with the treatment, antibiotic resistance, regulatory challenges, and availability of limited treatment options, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global epidural abscess treatment is segmented based on type, treatment, end-user, and region.
The surgery segment accounted for approximately 56.5% of the global epidural abscess treatment market share
The surgery segment is expected to hold the largest market share over the forecast period. Epidural abscess is a rare infection of the lumbar spine, with the highest prevalence in the lumbar spine (50%), followed by the thoracic spine (38%) and cervical spine (12%).
According to the Frontiers research publication in August 2023, surgery is the initial treatment option for epidural abscesses, and it is usually combined with antibiotic therapy. A classic surgical procedure is a total laminectomy, which requires the spinous process and both vertebral lamina to be taken out, as well as a portion of the posterior longitudinal ligament to be cut to open the intervertebral space and drain the abscess.
Surgery involves draining the abscess and removing any infected tissue. This can help to prevent the abscess from spreading and causing further damage. For instance, in 2022, globally approximately 350 million spinal surgeries were performed.
Geographical Analysis
North America accounted for approximately 42.3% of the global epidural abscess treatment market share
North America region is expected to hold the largest market share over the forecast period owing to the mysterious increase in rare pediatric intracranial abscesses and high healthcare expenditures that are driving the market in this region.
Disease detectives with the US Centers for Disease Control and Prevention are investigating a cluster of rare and serious brain abscesses in kids in and around Las Vegas, Nevada, and doctors from other parts of the country say they may be seeing a rise in cases. In 2022, the number of brain abscesses in kids tripled in Nevada, rising from an average of four to five a year to 18.
The increasing prevalence of intravenous drug use and rising awareness among people regarding epidural abscesses, coupled with the surge in early detection and treatment, is propelling this market growth. For instance, as reported by the United Nations Office on Drugs and Crime in June 2023, there was a global estimate of 13.2 million people engaged in injecting drugs in 2021, signifying an 18% increase from the 11.2 million reported in 2020. Hence, the growing incidence of intravenous drug use is poised to be a significant driver of the epidural abscess treatment market's expansion.
Moreover, key players' strategies such as mergers and acquisitions would propel this market growth in this region. For instance, in March 2022, AbbVie announced it had completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.
This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder.
Market Segmentation
By Type
• Intracranial
• Intraspinal
By Treatment
• Antifungal Drugs
• Antibiotics
• Surgery
By End-user
• Hospitals
• Specialty clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the epidural abscess treatment market include Alembic Ltd, Eli Lilly and Company, Sandoz Group Inc., Sun Pharmaceutical Industries Ltd, Novartis AG, Sanofi, Abbott, Merck & Co., Inc., Pfizer Inc., Siemens Healthineers AG among others.
Key Developments
 In December 2023, AbbVie Inc. and Cerevel Therapeutics announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet needs remain for patients.
 In May 2023, Omeq Medical received the US Food and Drug Administration (FDA) approval for its EpiFinder smart device. EpiFinder is a sensor-based, battery-operated single-use epidural placement device, intended for the safe and accurate delivery of epidural injections.
 In December 2022, Abbott announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
Why Purchase the Report?
• To visualize the global epidural abscess treatment market segmentation based on type, treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of epidural abscess treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global epidural abscess treatment market report would provide approximately 62 tables, 51 figures, and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End-user
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Neurological Disorder
4.1.1.2. Advancements in Treatment and Digital Health Technologies
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Intracranial *
6.3. Intraspinal
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.2. Market Attractiveness Index, By Treatment
7.3. Antifungal Drugs *
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Antibiotics
7.5. Surgery
8. By End-user
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
8.1.2. Market Attractiveness Index, By End-user
8.2. Hospitals *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty clinics
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Alembic Ltd *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Eli Lilly and Company
11.3. Sandoz Group Inc
11.4. Sun Pharmaceutical Industries Ltd
11.5. Novartis AG
11.6. Sanofi
11.7. Abbott
11.8. Merck & Co., Inc
11.9. Pfizer Inc
11.10. Siemens Healthineers AG
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us